Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND)

Inclusion Criteria: * Women with chronic pelvic pain secondary to endometriosis surgically treated, with refractory symptoms, and who are taking complementary hormone therapy; * Women over 18 years of age who wish to participate in the clinical trial; * Willingness to voluntarily participate in the study to accept randomization to either of the two treatment arms; * Participating exclusively in this clinical trial during the study period; * Possess a telephone (cell or landline) that may be available to receive daily calls throughout the study period; * Signature of the Free and Informed Consent Term (TCLE) approved by the Local Research Ethics Committee. Exclusion Criteria: * Chronic, severe or uncompensated medical conditions, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled high blood pressure, lung disease such as asthma or other chronic obstructive pulmonary disease; hematological diseases, liver diseases, chronic kidney disease in advanced stage (grade 3, 4 and 5), metabolic disturbances and immunosuppression; * Use of any medication with potential interaction with CBD/THC (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this medications; * Inability to use oral medication; * Pregnancy or lactation; * History of alcohol or drug addiction; * Smoking in the last three years; * Marijuana use in the past three months or a lifetime history of dependence; * Inability to cooperate with investigators due to cognitive impairment or mental status.